Trial Profile
Phase 2 Study Assessing the Tolerance and Efficacy of Tamoxifen Alone Versus the Association Tamoxifen-RAD001 (Everolimus) in Patients With Anti-aromatase Resistant Breast Metastatic Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Tamoxifen
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms TAMRAD
- 07 Nov 2018 Status changed from active, no longer recruiting to completed.
- 07 May 2012 Primary endpoint 'Objective-clinical-response-rate' has been met according to results published in the Journal of Clinical Oncology.
- 07 May 2012 Results published in the Journal of Clinical Oncology.